A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

(2013) A. K. Burnett et al.   BLOOD

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

(2013) F. Efficace et al.   HAEMATOLOGICA

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

(2012) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

(2011) R. K. Hills et al.   BLOOD

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

(2011) A K Burnett et al.   LEUKEMIA

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

(2010) Utz Krug et al.   LANCET

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

(2009) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

(2009) Keith Wheatley et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY